Fig. 1 | British Journal of Cancer

Fig. 1

From: A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Fig. 1The alternative text for this image may have been generated using AI.

PG545 clinical activity. Cancer type, dose and subject ID indicated for the 23 subjects on trial and weeks on trial are shown in the swim plot. Dashed bars (subjects 2061 and 2062) indicate that subjects stopped receiving PG545 due to investigator discretion but stayed on study until 8 week assessment. # Subject stayed on study after PD erroneously classified as SD at 8 week. mCRC metastatic colorectal cancer, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, SCC squamous cell carcinoma, RCC renal cell carcinoma

Back to article page